Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of imatinib plus everolimus (RAD001) in advanced chordoma
2010-021755-34Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib and everolimus in chordoma, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Overall tumor response rate at 6 months (Choi criteria). Started Sep 2010; status: completed.
02
Drugs
imatinibeverolimus
03
Conditions
chordoma
Beyond the preview
Go deeper on 2010-021755-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021755-34.